<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01351818</url>
  </required_header>
  <id_info>
    <org_study_id>FER-SOM-2004-01</org_study_id>
    <nct_id>NCT01351818</nct_id>
  </id_info>
  <brief_title>Adipocyte Function and Somtropin Deficiency</brief_title>
  <acronym>FAYDS</acronym>
  <official_title>The Fayds Project: Adipocyte Function and Somtropin Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferring SAU</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the influence of exogenous GH (growth hormone) administration on adipocyte
      endocrine function (leptin, adiponectin, and resistin) and on ghrelin secretion in children
      with delayed growth due to GH deficiency.

      Study hypothesis: hormones produced by the adipocyte (leptin, adiponectin, and resistin) and
      ghrelin may exert a certain control on production of GH and IGF-I, and GH may in turn have a
      regulatory effect on such hormones.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the potential influence of exogenous GH administration on adipocyte endocrine function (leptin, adiponectin, and resistin) and on ghrelin secretion</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Height assessment (using Harpenden stadiometer)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight assessment</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI assessment</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">62</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>Growth hormone</arm_group_label>
    <description>Patients with a condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Growth Hormone</intervention_name>
    <arm_group_label>Growth hormone</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children with GH deficiency
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children of both sexes aged from 5 to 12 years, Tanner stage 1, with no signs of
             imminent pubertal development. Amenable to treatment with recombinant somatropin in
             the approved indication of low growth due to GH deficiency

          -  Selection of recombinant somatropin by the physician in the treatment authorization
             request, and subsequent approval of such treatment by the relevant growth hormone
             committee

          -  Body Mass Index (BMI) within ±1 SD

        Exclusion Criteria:

          -  Children with any of the reported contraindications for treatment with recombinant
             somatropin, existence of active neoplasms, progression or recurrence of intracranial
             lesion, etc. will not be studied

          -  Diabetes mellitus

          -  Intestinal inflammatory disease

          -  Celiac disease

          -  Uncontrolled hyperthyroidism

          -  AIDS

          -  Other diseases causing chronic malabsorption, hypercatabolism or malnutrition
             conditions

          -  Chronic liver disease

          -  Eating disorders: anorexia, bulimia, etc

          -  Long-term treatment with anti-obesity drugs or drugs causing malabsorption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Don Benito</city>
        <state>Badajoz</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Badajoz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Cáceres</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Cádiz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Huelva</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Jaen</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2011</study_first_submitted>
  <study_first_submitted_qc>May 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2011</study_first_posted>
  <last_update_submitted>May 10, 2011</last_update_submitted>
  <last_update_submitted_qc>May 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Clinical Development Support</name_title>
    <organization>Ferring Pharmaceuticals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

